Surgical Oncology News

This section features a sampling of news related to surgical oncology from the popular press, from press releases received, or SSO news directly pertinent to SSO members.

FDA advances RPCI spinoff's research

Author: Tracey Drury, Business First
Jan 18, 2011

A Buffalo biopharmaceutical company has received orphan drug status from the U.S. Food and Drug Administration for a pancreatic cancer inhibitor compound.

CureFAKtor Pharmaceuticals LLC, a spin-off from Roswell Park Cancer Institute, focused on the research and development of focal adhesion kinase (FAK). Its lead compound, CFAK-C4, is being developed for the treatment of pancreatic cancer.

The FDA awards orphan status to drugs and biologics that are being developed to treat rare medical conditions, specifically those affecting fewer than 200,000 persons in the U.S.

CureFAKtor was founded in 2008 by [SSO Member and Past President] Dr. William Cance shortly after he joined Roswell Park as chairman of surgical oncology and surgeon-in-chief. To date, the private company has been funded primarily by grants from the National Institutes of Health...

Read More on This Story Here...

Read More Surgical Oncology News Stories...